This website is intended for South African audience only
Promotion of Access to Information Act (PAIA)
The PAIA manual is prepared in accordance with section 51 of the Promotion of Access to Information Act (PAIA) No. 2 of 2000 (as amended) and the Protection of Personal Information Act, 2013. The purpose of PAIA is to promote the right of access to information, to foster a culture of transparency and accountability within the Company by giving the right to information that is required for the exercise or protection of any right and to actively promote a society in which the people of South Africa have effective access to information to enable them to exercise and protect their rights.
Consumer safety is always of the highest priority in GSK Consumer Health. Reports relating to safety are investigated and reported to the authorities by GSK as appropriate. Always use this product in accordance with the labelled instructions. To report an adverse event or complaint, please contact GSK on email@example.com, firstname.lastname@example.org
S0 ENO ACTIVE FRUIT SALT REGULAR (POWDER). Each 5,0 g dose contains: Sodium Bicarbonate 2,32 g; Anhydrous Citric Acid 2,18 g; Sodium Carbonate 0,50 g, Reg. No.: Y/11.4/185. Namibia: NS0 Reg. No: 12/11.4/0054. Botswana: S4 Reg. No.: BOT1703153. Zambia Reg. No.: 025/016.
S0 ENO ACTIVE FRUIT SALT ORANGE (POWDER). Each 5,0 g dose contains: Sodium Bicarbonate 2,29 g; Anhydrous Citric Acid 2,16 g; Sodium Carbonate 0,50 g. Reg. No.: Y/11.4/187.
Bottles containing 100 g and 200 g. Packs of 72 x 5 g sachets. Travel packs of 10 x 5 g or 20 x 5 g sachets.
S0 ENO ACTIVE FRUIT SALT (POWDER) Each 5,0 g dose contains: Sodium Bicarbonate 2,29 g; Anhydrous Citric Acid 2,16 g; Sodium Carbonate 0,50 g; ***Cooling Flavour Evercool. Reg no.: Y/11.4/186.
S0 ENO ACTIVE FRUIT SALT MINT FLAVOUR (POWDER) Each 5,0 g dose contains: Sodium Bicarbonate 2,32 g; Anhydrous Citric Acid 2,18 g; Sodium Carbonate; 0,50 g; ***Cooling Flavour Evercool. Reg no.: Z/11.4/13.
1. 6 symptoms of heartburn. List of 6 Symptoms: 1. Bitter or sour taste in mouth 2. Burning sensation in throat 3. Burning sensation in chest 4. Burning sensation in stomach 5. Stomach discomfort 6. Heaviness**
** Due to acid indigestion or gastric acid
Reference: Roger Jones and Karen Ballard. Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. European Journal of Gastroenterology & Hepatology 2008, 20;260-275. FDA, 21CFR331.11(d), 2019.
ENO gets to work in 6 seconds*: *Johnson S and Suralik J. A Comparison of the Effect of Regular ENO and Placebo on Intragastric pH. Practical Gastroenterology 2009, 28-32.
GlaxoSmithKline Consumer Healthcare South Africa (Pty) Ltd. Co. 39 Hawkins Avenue, Epping Industria 1, 7460, Cape Town. Reg. No.: 2014/173930/07. For full prescribing information refer to the professional information approved by the medicines regulatory authority. Always read label before use. All trademarks are owned by or licensed to the GSK group of companies. For any further information, including safety, please contact the GSK Hotline on +27 11 745 6001 or 0800118274.